Rob Swanda, Biologics Innovator and Science Communicator, shared on X:
“Zongertinib is a targeted therapy designed specifically for HER2‑mutant NSCLC, blocking the abnormal signals that make cancer cells grow. It works by shutting down HER2’s overactive kinase activity.
Learn the mechanism in my video with Cracking Cancer Podcast.”
You can also read:
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
